Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Delaware 94-3136539 (mark one) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12400 INCYTE CORPORATION (Exact name of registrant as specified in its charter) (State of othe ...

The upcoming report from Incyte (INCY) is expected to reveal quarterly earnings of $1.21 per share, indicating an increase of 95.2% compared to the year-ago period. Analysts forecast revenues of $1.02 billion, representing an increase of 10.2% year over year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Ahead of a company's earnings disclosu ...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced it has entered into an asset purchase agreement with MorphoSys AG (FSE: MOR; NASDAQ: MOR) which gives Incyte exclusive global rights for tafasitamab, a humanized Fc-modified CD19-targeting immunotherapy marketed in the U.S. as Monjuvi® (tafasitamab-cxix) and outside of the U.S. as Minjuvi® (tafasitamab). “This new agreement with MorphoSys provides Incyte with exclusive global rights to tafasitamab and full control over its development and ...

Incyte’s (INCY) performance in 2023 was tepid as pipeline setbacks and competition for lead drug Jakafi weighed on shares.Lead drug Jakafi (ruxolitinib) posted 8% growth in sales in the first three quarters of 2023.However, the FDA approval of GSK plc’s (GSK) momelotinib, under the brand name Ojjaara, for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera and post-essential thrombocythaemia), in adults with anemia, pos ...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2023 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 13, 2024. The schedule for the press release and conference call/webcast is as follows: Q4 & YE 2023 Press Release: February 13, 2024 at 7:00 a.m. ET Q4 & YE 2023 Conference Call: February 13, 2024 at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-38 ...

Incyte Corporation (NASDAQ:INCY) Q3 2023 Earnings Call Transcript October 31, 2023 8:00 AM ET Company Participants Ben Strain - Head of Investor Relations Herve Hoppenot - President and Chief Executive Officer Barry Flannelly - Executive Vice President and General Manager, North America Pablo Cagnoni - President and Head of Research and Development Steven Stein - Executive Vice President and Chief Medical Officer Christiana Stamoulis - Executive Vice President and Chief Financial Officer Conference Call Par ...

Incyte . xx Key Highlights Hervé Hoppenot Chief Executive Officer R&D Update Steven Stein Chief Medical Officer 2 3 HERVÉ HOPPENOT - CEO (Incyte) 5 | --- | --- | --- | --- | --- | --- | --- | --- | --- | |------------------------|-------------------------------------|-------|-------|-------|-------|-------------------------------------------------------|-------|-------| | | Standard Benefit \nBeginning 2025 | 2025 | 2026 | 2027 | 2028 | Specified Small Manufacturer Phase-In Schedule \n2029 | 2030 | 2031 | | ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12400 INCYTE CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdict ...

Incyte Corporation (NASDAQ:INCY) Q2 2023 Earnings Call Transcript August 1, 2023 8:00 AM ET Company Participants Greg Shertzer - Investor Relations Herve Hoppenot - President and Chief Executive Officer Pablo Cagnoni - President, Head of Research & Development Barry Flannelly - Executive Vice President and General Manager, North America Steven Stein - Executive Vice President and Chief Medical Officer Christiana Stamoulis - Executive Vice President and Chief Financial Officer Conference Call Participants Kr ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12400 INCYTE CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction o ...